#United States #Louisville #Sarcoma #US WorldMeds #TECELRA

US WorldMeds Receives the Vision of Hope Award

On October 6, 2026, US WorldMeds was honored with the prestigious 2026 Vision of Hope Award by the Sarcoma Foundation of America (SFA) during the Stand Up to Sarcoma Gala held in New York City. This recognition highlights the company’s significant contributions to innovating treatment options for sarcoma, specifically through its dedication to integrating patient advocacy into its developmental and regulatory practices.

The Vision of Hope Award was previously awarded to Adaptimmune in 2022 for their groundbreaking work on TECELRA® (afamitresgene autoleucel). After acquiring TECELRA in 2025, US WorldMeds has dedicated itself to obtaining comprehensive FDA approval for the therapeutic product, while also exploring new treatment avenues for those affected by sarcoma.

The SFA emphasized US WorldMeds' relentless commitment to enhancing treatment options and how the company actively engages with the sarcoma community, valuing and integrating patient feedback into its efforts. This collaborative approach has been recognized as a blueprint for industry-advocacy partnerships aimed at improving patient care and outcomes.

Breck Jones Jr., President of US WorldMeds, expressed gratitude for the award, stating, “Sarcoma continues to be an underfunded and underserved area in healthcare. Those living with this condition deserve collaborators who listen attentively as well as invest in meaningful action.” He dedicated the award to the patients, caregivers, and advocates who continually inspire the company's mission and influence the trajectory of its science.

In response to the award, Brandi Felser, Chief Executive Officer of the Sarcoma Foundation of America, praised US WorldMeds for its rapid and impactful contributions to the sarcoma community. She noted, “Their dedication to meaningfully incorporating the patient voice is an innovative and progressive approach.”

About TECELRA

TECELRA is a specialized T cell immunotherapy targeting the melanoma-associated antigen A4 (MAGE-A4). It is designed for treating adults and pediatric patients aged 12 and above suffering from unresectable or metastatic synovial sarcoma who have undergone prior chemotherapy and meet specific HLA positivity criteria, while also having tumors that express the MAGE-A4 antigen.

Important Safety Information

Patients should be aware that receiving TECELRA requires hospitalization both before and after treatment. The therapy is known to induce side effects that may be severe, including fever, chills, difficulty breathing, and severe gastrointestinal disturbances, requiring immediate medical attention.

Patients are advised to stay close to a healthcare facility for at least two weeks post-treatment and to comply with follow-up blood tests to monitor health progress. Thorough medical disclosure of all medications, supplements, and health conditions to healthcare providers is imperative prior to initiating treatment with TECELRA.

The most common side effects associated with TECELRA include nausea, fatigue, fever, and infections among others. Side effects should be reported to the FDA at (800) FDA-1088 and additionally to US WorldMeds at 1-855-246-9232.

Conclusion

US WorldMeds is making strides in the pharmaceutical industry with its focus on rare and specialty treatments. Their collaborative approach with the sarcoma community and commitment to patient advocacy have established them as leaders in this niche sector. As they continue to develop effective therapies such as TECELRA, they aim to set new standards in care for those battling sarcoma.